Travere Therapeutics (TVTX) Free Cash Flow (2011 - 2026)

Travere Therapeutics has reported Free Cash Flow for 16 years, with the latest figure at -$40.4 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 4.33% year-over-year to -$40.4 million; the trailing twelve-month figure through Mar 2026 stood at $39.5 million (up 125.73% YoY), and the FY2025 full-year result was $37.8 million, up 116.43% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$40.4 million, down from $60.7 million in the prior quarter.
• The five-year high for Free Cash Flow was $60.7 million in Q4 2025, with the low at -$118.9 million in Q1 2024.
• Historically, Free Cash Flow has averaged -$48.2 million across 5 years, with a median of -$42.5 million in 2024.
• Annual changes were most pronounced in 2022 — Free Cash Flow sank 675.99% — and 2025, when it surged 314.65%.
• Travere Therapeutics' Free Cash Flow stood at -$76.7 million in 2022, then advanced by 16.08% to -$64.4 million in 2023, then surged by 56.1% to -$28.3 million in 2024, then surged by 314.65% to $60.7 million in 2025, then sank by 166.52% to -$40.4 million in 2026.
• The last three Free Cash Flow figures came in at -$40.4 million (Q1 2026), $60.7 million (Q4 2025), and $14.2 million (Q3 2025), per Business Quant data.